However, immune checkpoint activation limits the efficacy of mIDH1 inhibitors and restores the normal recruitment of CD8+ T cells thereby reducing tumor drug resistance and improving therapeutic efficacy 41. The gene discussed is CD8A; the disease is neoplasm.